TY - JOUR T1 - High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study JF - Gut JO - Gut SP - 2605 LP - 2608 DO - 10.1136/gutjnl-2021-326755 VL - 71 IS - 12 AU - Midas B Mulder AU - Annemiek A van der Eijk AU - Corine H GeurtsvanKessel AU - Nicole S Erler AU - Brenda C M de Winter AU - Wojciech G Polak AU - Herold J Metselaar AU - Caroline M den Hoed Y1 - 2022/12/01 UR - http://gut.bmj.com/content/71/12/2605.abstract N2 - We read with great interest the recent publication from Siegel and colleagues, reporting recommendations from an international consensus meeting for SARS-CoV-2 vaccination in patients with inflammatory bowel diseases (IBDs).1 Based on experiences with other vaccines, it is reported that several immunosuppressive agents are associated with suboptimal vaccine response in patients with IBD.We assessed the effect of immunosuppressive blood levels on the SARS-CoV-2-specific immunogenicity of SARS-CoV-2 vaccination in liver transplant (LT) recipients vaccinated with two doses of the mRNA vaccines: BNT162b2 or mRNA-1273 or the vector vaccine ChAdOx1 nCoV-19. Excluded were patients with a history of a SARS-CoV-2 infection.A total of 476 LT recipients (476/795=59.9% of all alive recipients) were eligible for analysis between March and July 2021 at the Erasmus University Medical Centre (Rotterdam, the Netherlands). In total, 36 LT recipients had a history of a SARS-CoV-2 infection confirmed by PCR before vaccination, 128 LT recipients were not vaccinated and 155 LT recipients were not routinely seen at the outpatient clinic during the study period and, therefore, excluded from this analysis. Immunogenicity to vaccination was measured by using the Liaison SARS-CoV-2 TrimericS IgG assay (DiaSorin, Italy). Table 1 presents the … ER -